Should I Buy IBRX? IBRX 2026 Analysis

Should You Buy Immunitybio Inc (IBRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

5.910

1 Day change

-3.90%

52 Week Range

8.280

Analysis Updated At

2026/01/29

Buy now for a long-term investor: the trend is bullish (SMA5>SMA20>SMA200, price above pivot), options positioning is strongly call-skewed (very low put/call ratios), and Wall Street just reiterated/raised a Buy target ($9). The near-term overhang is event-driven (trial uncertainty headlines + law-firm investigation), but the most recent fundamental/stock catalyst is constructive FDA/regulatory dialogue around ANKTIVA in bladder cancer, which is the key driver for re-rating if execution continues.

Technical Analysis

Price closed at 6.27 (+3.36% regular session; +1.95% post). Trend is bullish with moving averages stacked positively (SMA_5 > SMA_20 > SMA_200), supporting a sustained uptrend bias. MACD histogram is positive (0.245) but contracting, implying upside momentum remains but is cooling (more prone to consolidation than a straight-line rally). RSI(6)=65.16 is neutral-to-slightly-warm (not an extreme), consistent with a rising trend that is not yet clearly overbought. Key levels: pivot support ~5.65; resistance R1 ~7.72 (first major upside zone). With price above pivot and trend structure bullish, the technical setup favors buying vs waiting, for an impatient long-term beginner. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options sentiment is strongly bullish: open interest put/call ratio is 0.21 and volume put/call ratio is 0.11, showing heavy call positioning relative to puts. Volume is elevated (today vs 30D average ~150%), suggesting active participation/attention. Implied volatility is very high (30D IV ~104%) vs historical volatility (~59%), indicating the market is pricing large moves; however, the skew in positioning is clearly risk-on (call-dominant) rather than defensive.

Technical Summary

Sell

Buy

Positive Catalysts

1) Regulatory momentum: recent positive FDA discussions for ANKTIVA in bladder cancer (sparked a sharp stock surge and strong volume).
2) Commercial/geo expansion narrative supported by Jefferies raising PT to $9 and keeping Buy; mentions pipeline advancement and label-expansion paths (guidelines/BCG-naive data as future upside events).
3) Technical uptrend remains intact (bullish MA stack; price above pivot), which can attract trend-following buyers.
4) Options market is decisively call-skewed with elevated volume, consistent with bullish near-term sentiment.

Neutral/Negative Catalysts

1) Event-driven headline risk: Pomerantz LLP investigation tied to prior drop after uncertain glioblastoma trial results.
2) Recent volatility/whipsaws: sharp rally followed by a notable pullback indicates sentiment can flip quickly on biotech headlines.
3) Profitability is not yet established (latest quarter still a large net loss), which can limit valuation support between catalysts.

Financial Performance

Latest quarter: 2025/Q3. Revenue rose to $32.06M (+425.07% YoY), signaling accelerating commercialization/recognition. However, profitability remains weak: net income was -$67.25M (worse YoY by 21.55%), EPS -0.07 (worse YoY by 41.67%). Gross margin remained extremely high at 99.45% (slightly down), consistent with product/revenue mix but not yet offsetting operating costs. Net: strong top-line growth, but earnings are still loss-making—execution on commercialization and label expansion is the main path to improving the trajectory.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst action: Jefferies (2025-12-12) raised price target to $9 from $8 and reiterated Buy, citing execution on commercial expansion and regulatory progress for ANKTIVA (including broader geographic presence and pipeline advancement). Wall Street pro view (pros): regulatory progress and potential label expansions create a credible pathway to higher revenue and market penetration; continued execution could drive multiple re-ratings. Wall Street con view (cons): clinical-result uncertainty in parts of the pipeline can produce abrupt drawdowns; ongoing losses mean the story remains catalyst/execution-dependent. Influential/politician activity check: Hedge funds and insiders are neutral recently (no notable trend). No recent Congress trading data available, and no reported politician activity in the provided dataset.

3 Analyst Rating

Wall Street analysts forecast IBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBRX is 7.33 USD with a low forecast of 5 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 6.150

Low

Averages

7.33

High

Current: 6.150

Low

Averages

7.33

High

Jefferies

Buy

upgrade

$8 -> $9

AI Analysis

2025-12-12

Reason

Jefferies

Price Target

$8 -> $9

AI Analysis

2025-12-12

upgrade

Buy

Reason

Jefferies raised the firm's price target on ImmunityBio to $9 from $8 and keeps a Buy rating on the shares. The firm believes ImmunityBio is in execution mode to continue expanding the company's geographic and commercial presence and to advance the pipeline, and today's EMA conditional marketing authorization recommendation for Anktiva in NMIBC-CIS builds on existing approvals in the U.S. and U.K. The company is continuing regulatory dialogue on the papillary disease and also awaiting NCCN guideline decision and BCG-naive data in the second half of 2026 could be another label expansion opportunity, Jefferies adds.

Piper Sandler

Neutral -> Overweight

upgrade

2025-05-20

Reason

Piper Sandler

Price Target

2025-05-20

upgrade

Neutral -> Overweight

Reason

Piper Sandler upgraded ImmunityBio to Overweight from Neutral with a price target of $5, up from $4.25.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IBRX

Unlock Now

IBRX Should I Buy

IBRX Should I Buy

Should You Buy Immunitybio Inc (IBRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch